Category survey

PARKINSON DISEASE MODEL WITH INDUCID PLURIPOTENT CELLS BEARING THE E46K MUTATION IN ALPHA-SINUCLEINE, TO IDENTIFY PATHOGENIC ROUTES Investments < €500k Spain 2016    

PHENOTYPES AND HAPLOTIPOSES ASSOCIATED WITH INTERTURED GENEAL ALTERS, HUNTINGTON DISEASE Investments < €500k Spain 2016    

EVALUATION OF THE IMPACT OF IMAGE PET amyloid-BETA IN THE DIAGNOSIS AND CONTROL CLINIC OF patients with cognitive impairment EVALUATED BY SUSPECTED Alzheimer’s disease (AD). Investments < €500k Spain 2016    

DEVELOPMENT OF A NEW MODEL OF PARKINSON DISEASE BY nonhuman primates PLK2 overexpression of dopaminergic neurons Investments < €500k Spain 2016    

CLINICAL-GENETIC CORRELATIONS IN DEMENTIA AND FAMILY PRESERVED nonagenarian cognitively Investments < €500k Spain 2016    

STUDY OF THE ROLE OF THE ALPHA-KLOTHO SOLUBLE ISOFORM IN THE START AND PROGRESSION OF COGNITIVE DEFICITS: PRECIOUS DIAGNOSTIC MARKER, AND DIANA MOLECULA WITH THERAPEUTIC POTENTIAL Investments < €500k Spain 2016    

PATHOGENIC ROLE OF AUTOFAGIC / LYSOSOMAL DYSFUNCTION IN PARKINSON DISEASE: DIAGNOSIS AND NEW PRE-CLINICAL THERAPIES Investments < €500k Spain 2016    

Huntington’s disease: deciphering the key molecular level processes of toxic amyloid aggregates Investments < €500k Denmark 2016    

Structural biology of the LRP1-Abeta interaction Investments < €500k Denmark 2016    

Manipulation of the Direct/Indirect-Pathway Neurons in Striatum by Use of Genetically Reengineered Receptors to Restore Motor Function in Parkinsonian Mice Investments < €500k Denmark 2016    

Activated microglia regulate neuronal secretion of a-synuclein by exophagy through activation of neuronal JNK stress kinase Investments < €500k Denmark 2016    

Characterizing the glymphatic peri-vascular connectome and its disruption in Alzheimer’s disease Investments < €500k Denmark 2016    

Molecular basis of Parkinson’s Disease: the fate of cytotoxic oligomers under cell-like conditions Investments < €500k Denmark 2016    

Deep Brain Stimulation induced changes in monoaminergic neurotransmission and regional cerebral blood flow Investments < €500k Denmark 2016    

Molecular insights in inherited dementia disorders – Cerebrospinal fluid biomarkers and stem cell derived neuron pathology Investments < €500k Denmark 2016    

Deep Brain Stimulation: Effects on brain circuits and neurotransmission. Investments < €500k Denmark 2016    

Structure and transcriptome analyses in Multiple System Atrophy: from human brain to preclinical models Investments < €500k Denmark 2016    

Long-term survival of new brain cells – a stereological study Investments < €500k Denmark 2016    

Healthy Aging with Nitrate – (Attacking late onset Alzheimer’s Disease from the vascular side) Investments < €500k Denmark 2016    

MicroRNA as a biomarker in Parkinson’s Disease and Multiple System Atrophy Investments < €500k Denmark 2016    

Serotonin modulation of neurogenesis-coupled microglial responses in Alzheimer’s-like disease in mice Investments < €500k Denmark 2016    

Song and music as a communicative form of intervention in rehabilitation in connection with dementia Investments < €500k Denmark 2016    

Cognitive impairment in Parkinson’s disease: histological correlation of hypometabolism and cerebral atrophy in an animal model and the effect of cogntive stimulation in patients Investments < €500k Spain 2016    

STUDY BY NEUROIMAGEN OF THE CARRIERS OF THE MUTATION E46K OF THE ALPHA SINUCLEIN GENE AS A MODEL OF DISEASE BY BODIES OF LEWY IDIOPATICA Investments < €500k Spain 2016    

THE CD200-CD200R1 SYSTEM AS A THERAPEUTIC DIANA AND BIOMARKER IN NEUROLOGICAL DISEASES: PARKINSON’S DISEASE Investments < €500k Spain 2016    

ETHICAL AND LEGAL FRAMEWORK FOR PREDICTIVE DIAGNOSIS OF ALZHEIMER’S DISEASE: QUALITY OF LIFE OF INDIVIDUALS AT RISK AND THEIR CLOSE OTHERS Investments < €500k Spain 2016    

CLINICAL UTILITY OF 23 LOCI RELATED TO ALZHEIMER’S DISEASE IN SUBJECTS AT THE RISK OF CONVERSION TO DEMENTIA Investments < €500k Spain 2016    

Noradrenergic Mechanisms of Depression and L-DOPA-induced Dyskinesia in Parkinson’s Disease Investments < €500k Denmark 2016    

Endogenous prototoxins to ameliorate cognitive deficits in Alzheimer’s disease Investments < €500k Denmark 2016    

Identification and characterisation of mismatch repair associated factors involved in genomic instability associated with Huntington’s disease Investments < €500k Denmark 2016    

Determinants of mental capacity: Individual differences, age-related changes, and neurodegenerative decline Investments < €500k Denmark 2016    

Pathophysiology of REM sleep behaviour disorder in narcolepsy – do narcolepsy patients have increased risk of developing Parkinsonism? Investments < €500k Denmark 2016    

Effektmekanismen ved dyb hjernestimulation for Parkinsons sygdom belyst med magnetoencephalografi. Effect mechanism of deep brain stimulation for Parkinson’s disease illuminated with magnetoencephalography Investments < €500k Denmark 2016    

Investigating alpha-synuclein aggregate toxicity in cellula Investments < €500k Denmark 2016    

DEVELOPMENT OF PET TRACERS TO IMAGE THE PARASYMPATHETIC NERVOUS SYSTEM – WITH SPECIAL EMPHASIS ON PARKINSON’S DISEASE Investments < €500k Denmark 2016    

Establishment of Prion-like Parkinson model and testing of neuroprotective strategies Investments < €500k Denmark 2016    

Cellular and Genetic Mechanisms of Dopamine Transporter-associated Parkinsonism Investments < €500k Denmark 2016    

Investigating a-synuclein dependent neurodegeneration in two novel transgenic mouse lines modeling increased aggregation and lack of age-dependent trophic a-synuclein signalling Investments < €500k Denmark 2016    

Activation of Neuronal JNK following Endogenous Stress or Inflammatory Signaling Regulates the Unconventional Secretion of Alpha-Synuclein Investments < €500k Denmark 2016    

Testing predictions of quantitative models of dopamine signals in different stages of Parkinson’s disease. Investments < €500k Denmark 2016    

Molecular basis of Parkinson’s Disease: the fate of cytotoxic oligomers under cell-like conditions Investments < €500k Denmark 2016    

Combined anti-inflammatory- and iron chelation therapy in a preclinical model of neurodegeneration with brain iron accumulation Investments < €500k Denmark 2016    

Immune genes impact on development of a-synucleinopathy Investments < €500k Denmark 2016    

Modeling and correcting Huntington’s disease-associated myelin deficiency in human glial chimeras Investments < €500k Denmark 2016    

Exploring the links between Alzheimer´s Disease, Diabetes and Obesity – Is there Genetic Evidence of Inflammation and Insulin Resistance the Human Brain? Investments < €500k Denmark 2016    

aSYN minipig models of Parkinson’s disease for testing aSYN imaging agents and therapies Investments < €500k Denmark 2016    

Prolyl isomerases in neural development and aging Investments < €500k Czech Republic 2016    

The role of proteinase-activated receptors in pathogenesis of prion diseases Investments < €500k Czech Republic 2016    

RNA-demethylase FTO in the regulation of cognitive function and brain energy homeostasis: a novel pharmacological target in Alzheimer’s disease Investments < €500k Czech Republic 2016    

3-Nitro-L-tyrosine in structures of neurodegenerative proteins Investments < €500k Czech Republic 2016